China Remains at Risk to Future MonkeyPox Outbreaks.
GeoVax (GOVX) intends to become the first U.S.-based supplier of the MVA vaccine to prevent Mpox and smallpox.
Is There Enough Monkeypox (Mpox) Vaccine to go Around? Maybe yes, More Likely no.
Reported in Gates and Soda
As monkeypox cases continue to mount – topping 31,000 cases globally – governments of...
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
Major Mpox Outbreak in the Democratic Republic of Congo.
As Reported in NPR's Gates and Soda
Major Mpox Outbreak in the Democratic Republic of Congo is a...
Latest article
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...
